On February 24, 2026 Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, reported more than 15 abstracts featuring its urology portfolio will be presented at the 2026 ASCO (Free ASCO Whitepaper) Genitourinary Cancers Symposium (ASCO GU). The abstracts span studies across prostate and bladder cancers, featuring real-world data for Decipher Prostate and new insights from phase II clinical trials, including one utilizing the company’s upcoming TrueMRD Muscle-Invasive Bladder Cancer (MIBC) test. Collectively, these studies highlight how Veracyte’s Decipher and TrueMRD genomic tests are increasingly helping to guide clinical decision-making, advance biological understanding, and accelerate innovation in urologic cancer care. The conference will take place February 26-28 in San Francisco.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The breadth of data at ASCO (Free ASCO Whitepaper) GU shows how our Veracyte Diagnostics Platform is driving meaningful insight across multiple urologic cancers," said Elai Davicioni, Ph.D., Veracyte’s medical director, Urology. "In bladder cancer, Decipher is increasingly being integrated into studies that aim to help guide treatment decisions. With TrueMRD, our whole-genome sequencing minimal residual disease platform, we are extending the understanding of tumor evolution and treatment resistance, while also providing critical information to ensure the earlier detection of recurrent disease when a cure may still be achievable."
One of the key studies being presented is SURE‑02, a phase II trial examining how genomic subtyping with the Decipher Bladder test can inform treatment approaches in bladder cancer.
"The findings underscore the importance of molecular subtyping in muscle‑invasive bladder cancer and support the integration of genomic classifiers, such as the Decipher Bladder test, into clinical trial design, for the first time suggesting a biologically informed strategy for the use of anti-TROP2 ADCs," said Andrea Necchi, M.D., principal investigator of the SURE‑02 trial. "This approach enables a more rational selection of novel treatment strategies and represents an important step in aligning clinical research with precision‑based care."
Other highlights at the conference include an oral presentation with data on Veracyte’s upcoming TrueMRD MIBC test in the HCRN GU 20-444 response guided bladder-sparing trial and results for Decipher Bladder from NURE-combo and BLASST-01 trials:
Title:
Phase 2 trial of pembrolizumab (P) with response-guided bladder-sparing in patients with muscle-invasive bladder cancer (MIBC; HCRN GU 20-444).
Presenter:
Jonathan Anker, M.D., Ph.D., Mount Sinai Tisch Cancer Center
Format:
Rapid Oral Abstract Session
Abstract #:
737
Date/Time:
Friday, February 27, 2026, 4:00 – 4:45 PM PST
Location:
Level 3, Ballroom
Title:
Neoadjuvant sacituzumab govitecan (SG) plus pembrolizumab (Pembro), followed by response-adapted bladder sparing and adjuvant pembro, in patients with muscle-invasive bladder cancer (MIBC): SURE-02 primary analysis and biomarker results.
Presenter:
Andrea Necchi, M.D., IRCCS San Raffaele Hospital, Comprehensive Cancer Center
Format:
Poster (#H1)
Abstract #:
769
Date/Time:
Friday, February 27, 2026, 11:30 – 12:45 PM PST
Location:
Level 1, West Hall
Title:
Association of non-luminal subtype with overall survival in high-risk non-muscle invasive bladder cancer patients: Biomarker results from the Bladder Cancer Prognosis Programme.
Presenter:
Joep J. de Jong, M.D., Erasmus MC Cancer Institute, Rotterdam, Netherlands
Format:
Poster (#K23)
Abstract #:
843
Date/Time:
Friday, February 27, 2026, 11:30 – 12:45 PM PST
Location:
Level 1, West Hall
Title:
Association between non-luminal molecular subtypes and complete response rates after neoadjuvant chemo-immune therapy for muscle-invasive bladder cancer: Biomarker analyses of NURE-combo and BLASST-01 phase 2 clinical trials.
Presenter:
Joep J. de Jong, M.D., Erasmus MC Cancer Institute, Rotterdam, Netherlands
Format:
Poster (#K25)
Abstract #:
845
Date/Time:
Friday, February 27, 2026, 11:30 – 12:45 PM PST
Location:
Level 1, West Hall
Additionally, Veracyte continues to strengthen the connection of real-world data and outcomes to the Decipher Prostate test and the Decipher Genomics Research for Intelligent Discovery (GRID) platform, with several abstracts being showcased at the conference including:
Title:
Transcriptomic characterization of prostate cancer in patients with HIV infection.
Presenter:
Michael Leapman, M.D., Department of Urology, Yale School of Medicine
Format:
Poster (#M24)
Abstract #:
396
Date/Time:
Thursday, February 26, 2026, 11:30 – 12:45 PM PST
Location:
Level 1, West Hall
Title:
Comprehensive analysis of androgen production, uptake, and conversion (APUC) genes to highlight SRD5 family diversity in a large localized prostate cancer cohort.
Presenter:
Xiaolei Shi, M.D., University of Maryland School of Medicine
Format:
Poster (#M10)
Abstract #:
382
Date/Time:
Thursday, February 26, 2026, 11:30 – 12:45 PM PST
Location:
Level 1, West Hall
Veracyte’s Decipher team will be at Booth #48 at the 2026 ASCO (Free ASCO Whitepaper) GU Symposium. More information, including a full list of Decipher-focused abstracts being presented, can be found here.
About Decipher Prostate
The Decipher Prostate Genomic Classifier is a 22-gene test, developed using RNA whole-transcriptome analysis and machine learning, that helps inform treatment decisions for patients with prostate cancer. The test is performed on biopsy or surgically resected samples and provides an accurate risk of developing metastasis with standard treatment. Armed with this information, physicians can better personalize their patients’ care and may recommend less-intensive options for those at lower risk or earlier, more-intensive treatment for those at higher risk of metastasis. The Decipher Prostate test has been validated in many dozens of published studies involving more than 100,000 patients. It is the only gene expression test to achieve "Level 1B" evidence status and inclusion in the risk-stratification table in the most recent NCCN Guidelines* for prostate cancer. More information about the Decipher Prostate test can be found here.
About Decipher Bladder
The Decipher Bladder Genomic Classifier is a 219-gene test, developed using RNA whole-transcriptome analysis and machine learning, that is designed for use in patients following bladder cancer diagnosis who face questions regarding treatment intensity. The test classifies bladder tumors into five molecular subtypes, each having distinct tumor biology and potential clinical implications. This information can help physicians and their patients better understand the degree of benefit that would likely be gained from neoadjuvant chemotherapy and/or the likelihood of harboring non-organ-confined disease at time of surgery, respectively. More information about the Decipher Bladder test can be found here.
About Decipher GRID
The Decipher GRID database includes more than 200,000 whole-transcriptome profiles from patients with urologic cancers and is used by Veracyte and its partners to contribute to continued research and help advance understanding of prostate and other urologic cancers. GRID-derived information is available on a Research Use Only basis. More information about Decipher GRID can be found here.
About TrueMRD
Veracyte’s TrueMRD testing approach uniquely gives clinicians a comprehensive picture of their patient’s cancer status at every step, enabling them to personalize post-treatment care. From a small blood sample, we use AI and whole-genome sequencing to create a custom, molecular "fingerprint" for each patient’s tumor and then track the cancer’s recurrence and evolution over time. We plan to begin making our first TrueMRD test—for muscle-invasive bladder cancer—available to clinicians in the first half of 2026 and then expand to other cancers. More information about Veracyte’s TrueMRD testing approach can be found here.
(Press release, Veracyte, FEB 24, 2026, View Source [SID1234662933])